Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-94. doi:10.1016/j.ccr.2009.08.018
Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008;105(40):15535-40. doi:10.1073/pnas.0808266105
Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104(50):19971-6. doi:10.1073/pnas.0709313104
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. doi:10.1073/pnas.0506580102
Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005;106(8):2841-8. doi:10.1182/blood-2005-02-0488
Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-74. doi:10.1056/NEJMoa1301689
Joyce CE, Novina CD. miR-155 in acute myeloid leukemia: not merely a prognostic marker?. J Clin Oncol. 2013;31(17):2219-21. doi:10.1200/JCO.2012.48.3180
Miller PG, Al-Shahrour F, Hartwell KA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013;24(1):45-58. doi:10.1016/j.ccr.2013.05.004
Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014;14(3):329-41. doi:10.1016/j.stem.2013.12.016
DeAngelo DJ, Neuberg D, Amrein PC, et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014;38(4):430-4. doi:10.1016/j.leukres.2013.10.026